From: Becker's Supply Chain Report <>
Subject: EpiPen prescriptions spike despite controversy | What's in Allegan's new social contract? | A scary twist on opioids: 6 things to know about carfentanil | 110 physician leaders to know
View our profile on LinkedIn Follow us on Twitter Like us on Facebook Find us on Google+ View our videos on YouTube

Sept. 9, 2016

1. Mylan CEO: 55% of EpiPen price goes toward insurers, pharmacy benefit managers Full story
6 things to know about carfentanil: The deadly opioid invading the U.S.   Full story
3. Industry expert: EpiPens only cost $20 to make   
4. Upcoming webinar: Complicated, Costly and Common - The top high-cost, high-mortality procedures and how to manage them 
5. Allergan CEO pledges 'social contract' on drug prices 
6. Is Mylan really the bad guy? 4 thoughts from a leading healthcare strategist on the big picture of pharma price hikes   
7. Upcoming webinar: Solving the HAI equation; don't be obtuse, check all the angles  
8. EpiPen prescriptions spike in August despite pricing controversy 
110 physician leaders to know  Full story
10. New ad campaign defends drug industry's pricing tactic 
11. Mayo Clinic, radio station partner to pipe classical music into patient rooms  Full story

OHSU medical school dean dies 3 weeks after sustaining critical injuries  Full story
Call for submissions - "Supply chain tip of the week": If you would like to contribute a tip, insight or best practice related to improving the hospital supply chain, please email Mackenzie Bean at

Contact Us

Editorial Contact: 
Molly Gamble 
(800) 417-2035
Sales, Marketing & Events:
Jessica Cole
President and CEO

Becker's Hospital Review
A Becker's Healthcare Publication
35 E. Wacker Drive, Suite 1782 | Chicago, IL 60601
Becker's Healthcare, 35 E. Wacker, Suite 1782, Chicago, IL 60601
Sent by in collaboration with
Constant Contact